Clinical observation of low-dose decitabine combined with valproic acid in allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014888

Enrollment

Unknown

Registered

2018-02-12

Start date

2018-02-01

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancy

Interventions

experimental group:low-dose decitabine combined with valproic acid

control group:nothing

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) aged 14 to 60 years; (2) the diagnosis is in accordance with the guidelines formulated by the Chinese medical association's hematology division; (3) ECOG PS scores: 0 to 2; (4) the period of survival is estimated to be greater than 3 months; (5) the subjects volunteered and signed informed consent forms, and signed informed consent procedures to meet the requirements of the quality management specification (GCP) of the pharmaceutical clinical trials.

Exclusion criteria

Exclusion criteria: (1) the bone marrow cannot be absorbed through piercing; (2) diagnosing and merging other malignant tumors within 12 months prior to transplantation; (3) women in pregnancy or breastfeeding; (4)failing to control systemic fungi, bacteria or virus infection (defined as thetime of the symptoms/signs associated with infection, although the use of antibiotics or other treatment but still no improvement); (5) he is known or suspected to be allergic to the decitabine and valproic acid; (6) known human immunodeficiency virus (HIV) or the active stage virus infection of hepatitis b or c; (7) having a clear history of neurological or psychiatric disorders, including epilepsy or dementia; (8) according to the researchers' judgment, there is a serious riskof endangering the patient's safety, or the accompanying disease that affects the patient's completion of the research; (9) other clinical trials of other drugs were taken prior to the use of other experimental drugs.

Design outcomes

Primary

Measure	Time frame
myelogram;The occurrence of GVHD;	—

Secondary

Measure	Time frame
Blood routine;	—

Countries

China

Contacts

Public ContactGuo Rong

The First Affiliated Hospital of Zhengzhou University

gh7311@aliyun.com+86 18860398705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026